Calcitonin Gene Related Peptide (CGRP) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Calcitonin Gene Related Peptide (CGRP)- Pipeline Review, H2 2019’, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System and Immunology under development targeting Calcitonin Gene Related Peptide (CGRP).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)

– The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects

– The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide (CGRP) Overview

Calcitonin Gene Related Peptide (CGRP) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Calcitonin Gene Related Peptide (CGRP) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide (CGRP) Companies Involved in Therapeutics Development

Alder Biopharmaceuticals Inc

Eli Lilly and Co

Serometrix LLC

Teva Pharmaceutical Industries Ltd

Calcitonin Gene Related Peptide (CGRP) Drug Profiles

AFAP-3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit IL23 and CGRP for Autoimmune Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eptinezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fremanezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galcanezumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXL-41 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Calcitonin Gene Related Peptide (CGRP) Dormant Products

Calcitonin Gene Related Peptide (CGRP) Discontinued Products

Calcitonin Gene Related Peptide (CGRP) Product Development Milestones

Featured News & Press Releases

Jun 29, 2018: Alder BioPharmaceuticals Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine

Jun 29, 2018: Alder BioPharmaceuticals Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine

Jun 28, 2018: Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific Meeting

Jun 27, 2018: AHS 2018: Lilly Emgality (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX (onabotulinumtoxinA)

Jun 20, 2018: Alder BioPharmaceuticals to Present New Data Further Highlighting Eptinezumab's Efficacy Profile for Migraine Prevention at American Headache Society Meeting

Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

Jun 07, 2018: Alder BioPharmaceuticals Names Robert W. Azelby President and Chief Executive Officer

May 23, 2018: Teva Confirms September PDUFA Date for Fremanezumab

May 18, 2018: Teva Pharmaceutical Industries Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association

May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

May 15, 2018: Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association

Apr 25, 2018: Alder BioPharmaceuticals New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to

32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine

Apr 24, 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies

Apr 24, 2018: Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

Apr 23, 2018: Alder BioPharmaceuticals Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AfaSci Inc, H2 2019

Pipeline by Aptarion biotech AG, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by H. Lundbeck AS, H2 2019

Pipeline by Living Cell Technologies Ltd, H2 2019

Pipeline by Nepsone ehf, H2 2019

Pipeline by Pharmnovo AB, H2 2019

Pipeline by Serometrix LLC, H2 2019

Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports